Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

25 belated birthday claps for our one and only Sriracha-obsessed 🌶 intern, @luigikram! Throwing out an incredibly large Danke for all your hard work, fresh ideas & homemade bread! 🍞🥖🥯

Did you know that there are different types of #braintumors and that they can start as #cancer in other parts in the body? @MayoClinic is a great place to learn more about #braincancer, a disease we at #Noxxon strive to treat with #innovative #immunotherapies. https://t.co/VN1wPbtL9Y

ICYMI: #immunooncology innovator, Immunicum, announced positive results from a Phase I/II clinical trial examining their off-the-shelf #celltherapy, ilixadencel, in combination w/ TKIs in patients w/ GIST. See @biospace's summary of the news here: https://t.co/4UAsC9TCVK

ICYMI: #immunooncology innovator, Immunicum, announced positive results from a Phase I/II clinical trial examining their off-the-shelf #celltherapy, ilixadencel, in combination w/ TKIs in patients w/ GIST. See @biospace's summary of the news here: https://t.co/4UAsC9TCVK
Immunicum AB@Immunicum

Today we announced the results from our Phase I/II #clinicaltrial examining the safety & tolerability of our lead candidate, #ilixadencel in patients with Gastrointestinal Stromal Tumors (GIST). Click here to read the full press release: https://t.co/s0PzmMfz7J

Load More...